Duality Advisers, LP Alkermes Plc. Transaction History

Duality Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$26.4 - $32.56 $1.86 Million - $2.29 Million	70,389 New	70,389 $1.91 Million
Q3 2023 Nov 02, 2023	BUY	$27.17 - $31.97 $510,062 - $600,172	18,773 New	18,773 $525,000
Q4 2022 Feb 07, 2023	SELL	$21.94 - $26.24 $800,195 - $957,025	-36,472 Reduced 45.67%	43,393 $1.13 Million
Q3 2022 Nov 03, 2022	BUY	$22.0 - $31.87 $1.76 Million - $2.55 Million	79,865 New	79,865 $1.78 Million
Q2 2022 Aug 08, 2022	SELL	$26.4 - $30.54 $775,156 - $896,715	-29,362 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$23.07 - $27.99 $1.97 Million - $2.39 Million	-85,472 Reduced 74.43%	29,362 $773,000
Q4 2021 Feb 02, 2022	BUY	$21.47 - $32.08 $2.47 Million - $3.68 Million	114,834 New	114,834 $2.67 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $691,306 - $880,741	-37,963 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$15.39 - $22.1 $759,912 - $1.09 Million	-49,377 Reduced 56.53%	37,963 $757,000
Q3 2020 Nov 12, 2020	BUY	$16.16 - $20.66 $1.41 Million - $1.8 Million	87,340 New	87,340 $1.45 Million

359

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.18B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.